skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Although 10 of Japan’s largest pharma companies look set to add $11bn in revenues over the next nine years, a CAGR of only 1% reflects an expected $4.8bn in patent expiries, leaving Japanese pharma heads relying on innovation for the next phase of the region’s major wins.


Patent losses characterize Japan's challenging Pharma Future

For further information, context and expert analysis on Japan's pharma future follow the links below:

Pharma Report Store: Japan Pharma Outlook 2027

Webinar Discussing Japan Pharma

Innovation Critical As Japan Pharma Faces Continued Pricing Pressures








電話:+81 (0)3 6273 4260